Pfizer Inc.

What does Pfizer own?
Pfizer owns a portfolio of prescription medicines and vaccines spanning oncology, cardiovascular, immunology, vaccines, and rare diseases. Key products include Eliquis (anticoagulant), Prevnar (pneumococcal vaccine), Ibrance (breast cancer), Vyndaqel (rare heart disease), Paxlovid (COVID-19 antiviral), Comirnaty (COVID-19 vaccine, with BioNTech), and Abrysvo (RSV vaccine). The 2023 acquisition of Seagen added oncology antibody-drug conjugates including Padcev, Adcetris, and Tukysa. The 2025 acquisition of Metsera added obesity treatment candidates to the pipeline.

Is Pfizer publicly traded?
Yes, Pfizer Inc. is listed on the New York Stock Exchange under ticker PFE. The company has been publicly traded since 1944. Pfizer has no single controlling shareholder, with major institutional holders including Vanguard Group, BlackRock, and State Street. Pfizer is a component of the Dow Jones Industrial Average and the S&P 500.

Who founded Pfizer?
Pfizer was founded in 1849 in Brooklyn, New York by Charles Pfizer and his cousin Charles Erhart. Charles Pfizer was a German-born chemist who emigrated to the United States. The company's first product was santonin, an antiparasitic agent. Pfizer's breakthrough into modern pharmaceuticals came during World War II when the company developed large-scale penicillin production using deep-tank fermentation.

Where is Pfizer headquartered?
Pfizer is headquartered in New York City, New York, USA. The company maintains its principal executive offices in Midtown Manhattan. Pfizer operates manufacturing facilities in the United States, Belgium, Ireland, the United Kingdom, Germany, Japan, China, India, and Brazil, and sells products in more than 125 countries worldwide.

How many products does Pfizer sell?
Pfizer sells dozens of prescription medicines and vaccines across multiple therapeutic areas. The company's portfolio includes products in oncology, vaccines, cardiovascular, immunology, rare diseases, and hospital products. Several of Pfizer's products each generate over $1 billion in annual revenue, including Eliquis, Prevnar, Ibrance, and Vyndaqel. The company's research pipeline includes hundreds of compounds in various stages of clinical development.

Who owns Pfizer?
Pfizer Inc. is publicly traded on the NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. Major institutional shareholders include Vanguard Group, BlackRock, and State Street. Albert Bourla serves as Chairman and CEO. Pfizer has no founding family or private equity controlling shareholder.

What is Pfizer's financial performance?
For full-year 2025, Pfizer reported revenue of $62.6 billion, a 2% decrease from $63.6 billion in FY2024. Excluding COVID-19 products (Comirnaty and Paxlovid), revenue grew 6% operationally. Net income was $7.77 billion, down 3% from $8.03 billion. Adjusted diluted EPS was $3.22, up 4% from $3.11. Net cash from operations was $11.7 billion. For FY2026, Pfizer projects revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00.

Charles Pfizer and his cousin Charles Erhart founded Charles Pfizer and Company in Brooklyn, New York in 1849. The company's first product was santonin, an antiparasitic agent, which Pfizer made more palatable by mixing it with almond-toffee candy. This early focus on making medicines more acceptable to patients reflected a commercial instinct that would define the company.

Pfizer's first major commercial success came during the Civil War, when the company supplied large quantities of citric acid, tartaric acid, and cream of tartar to the Union Army. The company subsequently expanded into other fine chemicals and pharmaceutical ingredients.

Pfizer's breakthrough into modern pharmaceuticals came during World War II. The company developed a deep-tank fermentation process for producing penicillin in large quantities, making Pfizer the world's largest producer of penicillin by the end of the war. This manufacturing capability positioned Pfizer as a major force in the emerging antibiotic industry.

In 1950, Pfizer scientists discovered oxytetracycline (Terramycin), a broad-spectrum antibiotic. Pfizer marketed Terramycin directly to physicians, establishing the company's direct-to-physician sales model that became standard in the pharmaceutical industry.

Pfizer listed on the New York Stock Exchange in 1944. The company expanded internationally through the 1950s and 1960s, establishing subsidiaries in Europe, Latin America, and Asia.

The 1990s and 2000s were defined by blockbuster drugs and major acquisitions. Pfizer launched Viagra (sildenafil) in 1998 for erectile dysfunction, which became one of the most commercially successful drugs in history. Lipitor (atorvastatin), acquired through the 2000 merger with Warner-Lambert for approximately $90 billion, became the world's best-selling drug, generating peak annual revenues of approximately $13 billion.

Pfizer acquired Pharmacia in 2003 for approximately $60 billion, adding Celebrex and other products. The company acquired Wyeth in 2009 for approximately $68 billion, adding vaccines (Prevnar), biologics, and consumer healthcare products. Pfizer acquired Allergan's branded pharmaceutical business in 2016 for approximately $14 billion.

In 2020, Pfizer partnered with BioNTech to develop a COVID-19 mRNA vaccine. Comirnaty received emergency use authorization in December 2020 and became one of the most widely administered vaccines in history. Pfizer and BioNTech split revenues from Comirnaty, with Pfizer retaining approximately 50% of profits. Pfizer also developed Paxlovid, an oral COVID-19 antiviral, which received emergency use authorization in December 2021.

In 2023, Pfizer acquired Seagen, an oncology company specializing in antibody-drug conjugates, for approximately $43 billion. The acquisition significantly strengthened Pfizer's oncology pipeline and commercial portfolio, adding products including Padcev, Adcetris, and Tukysa.

In 2025, Pfizer acquired Metsera, a company developing obesity treatments, for approximately $10 billion. The acquisition marked Pfizer's entry into the obesity drug market, which has emerged as one of the fastest-growing pharmaceutical categories driven by GLP-1 receptor agonist therapies.

For full-year 2025, Pfizer reported revenue of $62.6 billion, a 2% decrease from FY2024. Excluding COVID-19 products, revenue grew 6% operationally. Net income was $7.77 billion, and adjusted diluted EPS was $3.22, up 4%. The company reaffirmed its 2026 guidance of $59.5 to $62.5 billion in revenue and adjusted diluted EPS of $2.80 to $3.00.

Pfizer has set science-based targets to reduce greenhouse gas emissions across its operations and supply chain. The company has committed to achieving carbon neutrality in its operations by 2040 and has implemented renewable energy programs across its manufacturing facilities. Pfizer achieved approximately 40% renewable energy usage as of 2024 and has invested in energy efficiency improvements and sustainable manufacturing processes.

In sustainable pharmaceutical development, Pfizer has focused on reducing environmental impact across its product lifecycle. The company has implemented programs to optimize manufacturing processes, reduce water usage in production, and develop more sustainable packaging solutions. Pfizer has also invested in green chemistry initiatives to reduce the environmental footprint of pharmaceutical synthesis.

Pfizer addresses ethical considerations through clinical trial ethics, responsible pricing, and global health access programs. The company maintains clinical trial standards and has implemented programs to improve medicine access in underserved communities through tiered pricing and donation programs. Pfizer's ethical guidelines emphasize patient safety, scientific integrity, and responsible marketing practices.

The Pfizer Foundation supports global health initiatives, healthcare education, and disaster relief. Pfizer employees volunteer thousands of hours annually, and the company provides support for healthcare professionals and patients through educational and support programs worldwide.

Pfizer is not a Certified B Corporation. The company publishes an annual ESG report and a 2025 Annual Review that includes sustainability disclosures.

Pfizer has received recognition in the pharmaceutical industry:

• Fortune Most Admired Companies (2024, 2025): Ranked among the world's most admired companies in pharmaceuticals
• Fast Company Most Innovative Companies: Multiple years of recognition for pharmaceutical innovation and vaccine development
• Science Magazine Top Employers (2024, 2025): Recognition for scientific research and innovation workplace
• Great Place to Work Certification (2024, 2025): Certification for workplace culture across multiple regions
• Galen Prize for Excellence in Pharmaceutical Research (2024): Recognition for breakthrough pharmaceutical research and development

Pfizer has faced significant regulatory and legal scrutiny throughout its history. In 2009, the company paid a $2.3 billion settlement to the US Department of Justice, the largest healthcare fraud settlement in US history at the time, related to the illegal promotion of Bextra and other drugs for off-label uses.

Pfizer's COVID-19 vaccine program generated both acclaim and controversy. While Comirnaty was credited with saving millions of lives globally, the company faced criticism regarding vaccine pricing, intellectual property protections that limited access in lower-income countries, and the speed of the regulatory process. Some critics questioned the liability protections that Pfizer and other vaccine manufacturers received under government contracts.

The company's Xeljanz (tofacitinib) faced regulatory scrutiny after a post-marketing safety study found increased risks of serious heart-related events and cancer compared to TNF inhibitors. The FDA required updated labeling and restricted the drug's use in certain patient populations.

In 2023, Pfizer faced a lawsuit from the state of Texas alleging that the company misrepresented the efficacy of its COVID-19 vaccine. Pfizer has defended the vaccine's safety and efficacy, citing clinical trial data and real-world evidence.

Pfizer, like all pharmaceutical companies, faces ongoing scrutiny over drug pricing practices, particularly in the United States where prescription drug costs are a political issue. The Inflation Reduction Act's drug price negotiation provisions, which allow Medicare to negotiate prices for certain high-cost drugs, could impact Pfizer's revenue on products selected for negotiation.